Amgen reports positive top-line results from Phase III trial of Repatha to treat LDL-C

Biotechnology company Amgen has reported positive top-line results from the Phase III clinical trial of Repatha (evolocumab) for the treatment of patients with low-density lipoprotein cholesterol (LDL-C).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news